{"filing":{"accession_number":"0001213900-26-094447","cik":"0001840877","ticker":"COCHW","company_name":"Envoy Medical, Inc.","form":"8-K","filing_date":"2026-08-27","report_date":"2026-08-24","primary_document":"ea0303543-8k_envoy.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1840877/000121390026094447/ea0303543-8k_envoy.htm"},"events":[{"id":30129,"run_id":27611,"accession_number":"0001213900-26-094447","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"The filing discloses the appointment of Robert Potashnick as Chief Accounting Officer and Vice President of Finance on August 24, 2026, transitioning from his prior role as Interim-CFO on a contractor basis. While the disclosure includes compensatory details (base salary of $315,000, 15% bonus target, and 250,000 stock options), the principal action is the formal appointment to a named executive officer position, making this an exec_appointment rather than exec_compensation. The appointment of a principal financial officer is material to investors assessing the company's financial leadership and governance.","company_name":"Envoy Medical, Inc.","ticker":"COCHW","filing_date":"2026-08-27","form":"8-K","submitted_at":null,"items":[{"id":32641,"accession_number":"0001213900-26-094447","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Robert Potashnick as Chief Accounting Officer and Vice President of Finance on August 24, 2026, transitioning from his prior role as Interim-CFO on a contractor basis. While the disclosure includes compensatory details (base salary of $315,000, 15% bonus target, and 250,000 stock options), the principal action is the formal appointment to a named executive officer position, making this an exec_appointment rather than exec_compensation. The appointment of a principal financial officer is material to investors assessing the company's financial leadership and governance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-27T21:30:45.739207+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":32641,"accession_number":"0001213900-26-094447","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Robert Potashnick as Chief Accounting Officer and Vice President of Finance on August 24, 2026, transitioning from his prior role as Interim-CFO on a contractor basis. While the disclosure includes compensatory details (base salary of $315,000, 15% bonus target, and 250,000 stock options), the principal action is the formal appointment to a named executive officer position, making this an exec_appointment rather than exec_compensation. The appointment of a principal financial officer is material to investors assessing the company's financial leadership and governance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-27T21:30:45.739207+00:00","company_name":"Envoy Medical, Inc.","ticker":"COCHW","filing_date":"2026-08-27"}]}